Microarray analysis in pulmonary hypertension

European Respiratory Journal

Volumn 48, Issue 1, 2016, Pages 229-241

  Hoffmann, Julia ^a   Wilhelm, Jochen ^b   Olschewski, Andrea ^a,c   Kwapiszewska, Grazyna ^a,c  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MICRORNA; UNTRANSLATED RNA; RNA;

CHRONIC LUNG DISEASE; DATA ANALYSIS; ENDOTHELIUM CELL; GENE EXPRESSION; GENE MUTATION; HUMAN; INFLAMMATION; LASER CAPTURE MICRODISSECTION; LUNG ALVEOLUS CELL; LUNG FIBROBLAST; LUNG HOMOGENATE; LUNG PARENCHYMA; MICROARRAY ANALYSIS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; REVIEW; RNA SEQUENCE; RODENT MODEL; ANIMAL; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPLICATION; DISEASE MODEL; DNA MICROARRAY; FIBROSING ALVEOLITIS; GENE EXPRESSION REGULATION; GENETICS; LUNG; METABOLISM; MOUSE; RAT;

ANIMALS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HUMANS; HYPERTENSION, PULMONARY; IDIOPATHIC PULMONARY FIBROSIS; LUNG; MICE; MICROARRAY ANALYSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RATS; RNA;

EID: 84977159753     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.02030-2015     Document Type: Review

References (85)

1. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62: 25 Suppl., D34-D41.
2. Seeger W, Adir Y, Barbera JA, et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol 2013; 62: 25 Suppl., D109-D116.
3. Castria D, Refini RM, Bargagli E, et al. Pulmonary hypertension in idiopathic pulmonary fibrosis: prevalence and clinical progress. Int J Immunopathol Pharmacol 2012; 25: 681-689.
4. Elwing J, Panos RJ. Pulmonary hypertension associated with COPD. Int J Chron Obstruct Pulmon Dis 2008; 3: 55-70.
5. Hoffmann J, Marsh LM, Pieper M, et al. Compartment-specific expression of collagens and their processing enzymes in intrapulmonary arteries of IPAH patients. Am J Physiol Lung Cell Mol Physiol 2015; 308: L1002-L1013.
6. Hoffmann J, Wilhelm J, Marsh LM, et al. Distinct differences in gene expression patterns in pulmonary arteries of patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis with pulmonary hypertension. Am J Respir Crit Care Med 2014; 190: 98-111.
7. Pullamsetti SS, Savai R, Janssen W, et al. Inflammation, immunological reaction and role of infection in pulmonary hypertension. Clin Microbiol Infect 2011; 17: 7-14.
8. Burke DL, Frid MG, Kunrath CL, et al. Sustained hypoxia promotes the development of a pulmonary artery-specific chronic inflammatory microenvironment. Am J Physiol Lung Cell Mol Physiol 2009; 297: L238-L250.
9. Foris V, Kovacs G, Tscherner M, et al. Biomarkers in pulmonary hypertension: what do we know? Chest 2013; 144: 274-283.
10. West JD, Austin ED, Gaskill C, et al. Identification of a common Wnt-associated genetic signature across multiple cell types in pulmonary arterial hypertension. Am J Physiol Cell Physiol 2014; 307: C415-C430.
11. Rhodes CJ, Wharton J, Boon RA, et al. Reduced microRNA-150 is associated with poor survival in pulmonary arterial hypertension. Am J Respir Crit Care Med 2013; 187: 294-302.
12. Mura M, Anraku M, Yun Z, et al. Gene expression profiling in the lungs of patients with pulmonary hypertension associated with pulmonary fibrosis. Chest 2012; 141: 661-673.
13. Hemnes AR, Trammell AW, Archer SL, et al. Peripheral blood signature of vasodilator-responsive pulmonary arterial hypertension. Circulation 2015; 131: 401-409.
14. Djebali S, Davis CA, Merkel A, et al. Landscape of transcription in human cells. Nature 2012; 489: 101-108.
15. Ruiz-Orera J, Messeguer X, Subirana JA, et al. Long non-coding RNAs as a source of new peptides. eLife 2014; 3: e03523.
16. Mestdagh P, Vandesompele J, Brusselle G, et al. Non-coding RNAs and respiratory disease. Thorax 2015; 70: 388-390.
17. Wei C, Henderson H, Spradley C, et al. Circulating miRNAs as potential marker for pulmonary hypertension. PloS One 2013; 8: e64396.
18. Consortium M, Shi L, Reid LH, et al. The MicroArray Quality Control (MAQC) project shows inter-and intraplatform reproducibility of gene expression measurements. Nat Biotechnology 2006; 24: 1151-1161.
19. Shi L, Campbell G, Jones WD, et al. The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnology 2010; 28(8): 827-838.
20. Reimers M. Statistical analysis of microarray data. Addict Biol 2005; 10: 23-35.
21. Huber W, von Heydebreck A, Sultmann H, et al. Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics 2002; 18: Suppl. 1, S96-104.
22. Sultan M, Amstislavskiy V, Risch T, et al. Influence of RNA extraction methods and library selection schemes on RNA-seq data. BMC Genomics 2014; 15: 675.
23. Wilhelm J, Muyal JP, Best J, et al. Systematic comparison of the T7-IVT and SMART-based RNA preamplification techniques for DNA microarray experiments. Clin Chem 2006; 52: 1161-1167.
24. Benes V, Muckenthaler M. Standardization of protocols in cDNA microarray analysis. Trends Biochem Sci 2003; 28: 244-249.
25. Hollingshead D, Lewis DA, Mirnics K. Platform influence on DNA microarray data in postmortem brain research. Neurobiol Dis 2005; 18: 649-655.
26. Brazma A, Vilo J. Gene expression data analysis. FEBS Lett 2000; 480: 17-24.
27. Do JH, Choi DK. Normalization of microarray data: single-labeled and dual-labeled arrays. Mol Cells 2006; 22: 254-261.
28. Durinck S. Pre-processing of microarray data and analysis of differential expression. Methods Mol Biol 2008; 452: 89-110.
29. Quackenbush J. Microarray data normalization and transformation. Nat Genet 2002; 32: Suppl., 496-501.
30. Gu S, Li G, Zhang X, et al. Aberrant expression of long noncoding RNAs in chronic thromboembolic pulmonary hypertension. Mol Med Rep 2015; 11: 2631-2643.
31. Geraci MW, Moore M, Gesell T, et al. Gene expression patterns in the lungs of patients with primary pulmonary hypertension: a gene microarray analysis. Circ Res 2001; 88: 555-562.
32. Rajkumar R, Konishi K, Richards TJ, et al. Genomewide RNA expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension. Am J Physiol Heart Circ Physiol 2010; 298: H1235-H1248.
33. Hsu E, Shi H, Jordan RM, et al. Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. Arthritis Rheum 2011; 63: 783-794.
34. Zhao YD, Yun HZ, Peng J, et al. De novo synthesize of bile acids in pulmonary arterial hypertension lung. Metabolomics 2014; 10: 1169-1175.
35. Laumanns IP, Fink L, Wilhelm J, et al. The noncanonical WNT pathway is operative in idiopathic pulmonary arterial hypertension. Am J Respir Cell Mol Biol 2009; 40: 683-691.
36. Patel NM, Kawut SM, Jelic S, et al. Pulmonary arteriole gene expression signature in idiopathic pulmonary fibrosis. Eur Respir J 2013; 41: 1324-1330.
37. Fantozzi I, Huang W, Zhang J, et al. Divergent effects of BMP-2 on gene expression in pulmonary artery smooth muscle cells from normal subjects and patients with idiopathic pulmonary arterial hypertension. Exp Lung Res 2005; 31: 783-806.
38. Costello CM, Howell K, Cahill E, et al. Lung-selective gene responses to alveolar hypoxia: potential role for the bone morphogenetic antagonist gremlin in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2008; 295: L272-L284.
39. Gou D, Ramchandran R, Peng X, et al. miR-210 has an antiapoptotic effect in pulmonary artery smooth muscle cells during hypoxia. Am J Physiol Lung Cell Mol Physiol 2012; 303: L682-L691.
40. Yu J, Wilson J, Taylor L, et al. DNA microarray and signal transduction analysis in pulmonary artery smooth muscle cells from heritable and idiopathic pulmonary arterial hypertension subjects. J Cell Biochem 2015; 116: 386-397.
41. Bull TM, Coldren CD, Moore M, et al. Gene microarray analysis of peripheral blood cells in pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 170: 911-919.
42. Ulrich S, Taraseviciene-Stewart L, Huber LC, et al. Peripheral blood B lymphocytes derived from patients with idiopathic pulmonary arterial hypertension express a different RNA pattern compared with healthy controls: a cross sectional study. Respir Res 2008; 9: 20.
43. Grigoryev DN, Mathai SC, Fisher MR, et al. Identification of candidate genes in scleroderma-related pulmonary arterial hypertension. Transl Res 2008; 151: 197-207.
44. West J, Cogan J, Geraci M, et al. Gene expression in BMPR2 mutation carriers with and without evidence of pulmonary arterial hypertension suggests pathways relevant to disease penetrance. BMC Med Genomics 2008; 1: 45.
45. Pendergrass SA, Hayes E, Farina G, et al. Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury. PloS One 2010; 5: e12106.
46. Risbano MG, Meadows CA, Coldren CD, et al. Altered immune phenotype in peripheral blood cells of patients with scleroderma-associated pulmonary hypertension. Clin Transl Sci 2010; 3: 210-218.
47. Cheadle C, Berger AE, Mathai SC, et al. Erythroid-specific transcriptional changes in PBMCs from pulmonary hypertension patients. PloS One 2012; 7: e34951.
48. Chesne J, Danger R, Botturi K, et al. Systematic analysis of blood cell transcriptome in end-stage chronic respiratory diseases. PLoS One 2014; 9: e109291.
49. Sarrion I, Milian L, Juan G, et al. Role of circulating miRNAs as biomarkers in idiopathic pulmonary arterial hypertension: possible relevance of miR-23a. Oxid Med Cell Longev 2015; 2015: 792846.
50. Kwapiszewska G, Wilhelm J, Wolff S, et al. Expression profiling of laser-microdissected intrapulmonary arteries in hypoxia-induced pulmonary hypertension. Respir Res 2005; 6: 109.
51. Fink L, Kohlhoff S, Stein MM, et al. cDNA array hybridization after laser-assisted microdissection from nonneoplastic tissue. Am J Pathol 2002; 160: 81-90.
52. Fink L, Kwapiszewska G, Wilhelm J, et al. Laser-microdissection for cell type-and compartment-specific analyses on genomic and proteomic level. Exp Toxicol Pathol 2006; 57: Suppl. 2, 25-29.
53. Erac Y, Selli C, Filik P, et al. Effects of passage number on proliferation and store-operated calcium entry in A7r5 vascular smooth muscle cells. J Pharmacol Toxicol Methods 2014; 70: 1-5.
54. Roh M, Song C, Kim J, et al. Chromosomal instability induced by Pim-1 is passage-dependent and associated with dysregulation of cyclin B1. J Biol Chem 2005; 280: 40568-40577.
55. Sivanathan L, Chow A, Wong A, et al. In vivo passage of human prostate cancer cells in mice results in stable gene expression changes affecting numerous cancer-associated biological processes. Prostate 2014; 74: 537-546.
56. Arias ME, Ross PJ, Felmer RN. Culture medium composition affects the gene expression pattern and in vitro development potential of bovine somatic cell nuclear transfer (SCNT) embryos. Biol Res 2013; 46: 452-462.
57. Hribal R, Jewgenow K, Braun BC, et al. Influence of culture medium composition on relative mRNA abundances in domestic cat embryos. Reproduct Domest Anim 2013; 48: 245-251.
58. Machado RD, Aldred MA, James V, et al. Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat 2006; 27: 121-132.
59. Huertas A, Perros F, Tu L, et al. Immune dysregulation and endothelial dysfunction in pulmonary arterial hypertension: a complex interplay. Circulation 2014; 129: 1332-1340.
60. Cahill E, Costello CM, Rowan SC, et al. Gremlin plays a key role in the pathogenesis of pulmonary hypertension. Circulation 2012; 125: 920-930.
61. Rhodes CJ, Im H, Cao A, et al. RNA sequencing analysis detection of a novel pathway of endothelial dysfunction in pulmonary arterial hypertension. Am J Respir Crit Care Med 2015; 192: 356-366.
62. Stacher E, Graham BB, Hunt JM, et al. Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med 2012; 186: 261-272.
63. Grunig G, Durmus N. Spotlight on inflammation in pulmonary hypertension. Am J Respir Crit Care Med 2015; 192: 913-915.
64. Stenmark KR, Nozik-Grayck E, Gerasimovskaya E, et al. The adventitia: essential role in pulmonary vascular remodeling. Compr Physiol 2011; 1: 141-161.
65. Panzhinskiy E, Zawada WM, Stenmark KR, et al. Hypoxia induces unique proliferative response in adventitial fibroblasts by activating PDGFβ receptor-JNK1 signalling. Cardiovasc Res 2012; 95: 356-365.
66. Stenmark KR, Gerasimovskaya E, Nemenoff RA, et al. Hypoxic activation of adventitial fibroblasts: role in vascular remodeling. Chest 2002; 122: 25 Suppl., 326S-334S.
67. Yildiz A, Kaya H, Ertas F, et al. Association between neutrophil to lymphocyte ratio and pulmonary arterial hypertension. Turk Kardiyoloji Dernegi Arsivi 2013; 41: 604-609.
68. Vansteenkiste J, Dooms C, Mascaux C, et al. Screening and early detection of lung cancer. Ann Oncol 2012; 23: Suppl. 10, x320-x327.
69. Stenmark KR, Meyrick B, Galie N, et al. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 2009; 297: L1013-L1032.
70. Biasin V, Chwalek K, Wilhelm J, et al. Endothelin-1 driven proliferation of pulmonary arterial smooth muscle cells is c-fos dependent. Int J Biochem Cell Biol 2014; 54: 137-148.
71. Kwapiszewska G, Chwalek K, Marsh LM, et al. BDNF/TrkB signaling augments smooth muscle cell proliferation in pulmonary hypertension. Am J Pathol 2012; 181: 2018-2029.
72. Hoshikawa Y, Nana-Sinkam P, Moore MD, et al. Hypoxia induces different genes in the lungs of rats compared with mice. Physiol Genomics 2003; 12: 209-219.
73. Gharib SA, Luchtel DL, Madtes DK, et al. Global gene annotation analysis and transcriptional profiling identify key biological modules in hypoxic pulmonary hypertension. Physiol Genomics 2005; 22: 14-23.
74. Weisel FC, Kloepping C, Pichl A, et al. Impact of S-adenosylmethionine decarboxylase 1 on pulmonary vascular remodeling. Circulation 2014; 129: 1510-1523.
75. Kay JM, Harris P, Heath D. Pulmonary hypertension produced in rats by ingestion of Crotalaria spectabilis seeds. Thorax 1967; 22: 176-179.
76. Spees JL, Whitney MJ, Sullivan DE, et al. Bone marrow progenitor cells contribute to repair and remodeling of the lung and heart in a rat model of progressive pulmonary hypertension. FASEB J 2008; 22: 1226-1236.
77. van Albada ME, Bartelds B, Wijnberg H, et al. Gene expression profile in flow-associated pulmonary arterial hypertension with neointimal lesions. Am J Physiol Lung Cell Mol Physiol 2010; 298: L483-L491.
78. Vaszar LT, Nishimura T, Storey JD, et al. Longitudinal transcriptional analysis of developing neointimal vascular occlusion and pulmonary hypertension in rats. Physiol Genomics 2004; 17: 150-156.
79. Caruso P, MacLean MR, Khanin R, et al. Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline. Arterioscler Thromb Vasc Biol 2010; 30: 716-723.
80. Moreno-Vinasco L, Gomberg-Maitland M, Maitland ML, et al. Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. Physiol Genomics 2008; 33: 278-291.
81. Tada Y, Laudi S, Harral J, et al. Murine pulmonary response to chronic hypoxia is strain specific. Exp Lung Res 2008; 34: 313-323.
82. Wu W, Dave NB, Yu G, et al. Network analysis of temporal effects of intermittent and sustained hypoxia on rat lungs. Physiol Genomics 2008; 36: 24-34.
83. White K, Loughlin L, Maqbool Z, et al. Serotonin transporter, sex, and hypoxia: microarray analysis in the pulmonary arteries of mice identifies genes with relevance to human PAH. Physiol Genomics 2011; 43: 417-437.
84. Dejana E. The role of wnt signaling in physiological and pathological angiogenesis. Circ Res 2010; 107: 943-952.
85. Maher CA, Kumar-Sinha C, Cao X, et al. Transcriptome sequencing to detect gene fusions in cancer. Nature 2009; 458: 97-101.